RENX.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 14:51):

Stats
Dzisiejszy wolumen	655 353
Średni wolumen	765 459
Kapitalizacja rynkowa	33.58M
EPS	£0 ( 2024-03-27 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.710
ATR14	£0.363 (1.43%)

Renalytix AI PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Renalytix AI PLC Finanse

Annual	2022
Przychody:	£3.40M
Zysk brutto:	£701 000 (20.60 %)
EPS:	£-0.560

FY	2022
Przychody:	£3.40M
Zysk brutto:	£701 000 (20.60 %)
EPS:	£-0.560

FY	2022
Przychody:	£2.97M
Zysk brutto:	£918 000 (30.91 %)
EPS:	£-0.780

FY	2021
Przychody:	£1.49M
Zysk brutto:	£633 000 (42.45 %)
EPS:	£-0.490

Financial Reports:

No articles found.

Renalytix AI PLC

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.